Vistagen Therapeutics, Inc. (VTGN)
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
Address
343 ALLERTON AVENUE
SOUTH SAN FRANCISCO, CA 94080
Founded
1998
Number of Employees
39
Website
http://www.vistagen.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)